Kailera Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KLRA | GPCR | MAZE | MBX | ENTX | 0NZU.IL | |
|---|---|---|---|---|---|---|
| Market cap | 1.66B | 1.45B | 1.85B | 2.53B | 540.90M | 14.42B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.0 | -9.6 | -10.5 | -13.2 | -5.7 | — |
| Price/book | 0.0 | 1.1 | 4.1 | 6.1 | 21.2 | 8.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −50.77% | −39.17% | +12.66% | +112.13% | 0.00% | −43.38% |
| Today | +1.75% | +0.05% | +3.50% | −4.58% | +1.97% | +1.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KLRA news ›Kailera Therapeutics to Participate in November Investor Conferences
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Shopify Sustains Rapid Growth with Revenue Up 32% and Free Cash Flow Margin of 22% Robo.ai Subsidiary Neurovia AI Highlights…
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 Topline data from KaiNETIC-1, KaiNETIC-2, and…
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Kailera is concurrently advancing KAI-7535 in a global Phase 2 clinical trial in people living with obesity or overweight. The trial initiated in April 2026, with data expected in 2027. HARBOR-1: HRS-7535 (KAI-7535) Phase 3 Trial in…
84,615,439 Common Stock of Kailera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2026.
These Common Stock will be under lockup for 181 days starting from 16-APR-2026 to... 84,615,439 Common Stock of Kailera Therapeutics, Inc are subject to a Lock-Up Agreement Ending on 14-O
Kailera Therapeutics Inc Presents New Phase 1 Data For Ribupatide Injection At EASD 2026 Annual Meeting
Kailera Therapeutics, Inc. announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual...
Kailera Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Kailera Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time KLRA price, Nasdaq stock exchange Relative Strength Chart Kailera Therapeutics, Inc. All financial news and data tailored to…
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Target Price of $42.75
Separately, Weiss Ratings cut Kailera Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday. Get Our Latest Report on Kailera Therapeutics NASDAQ KLRA opened at $10.00 on Friday. The stock has a market…
Kailera Therapeutics, Inc.'s (NASDAQ:KLRA) Lock-Up Period Will End on October 14th
Read Our Latest Stock Analysis on Kailera Therapeutics Shares of Kailera Therapeutics stock opened at $10.83 on Wednesday. The business's fifty day simple moving average is $15.41. The firm has a market cap of $1.40 billion and a P/E ratio…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketbeat.com3
- marketscreener.com3
- investors.kailera.com1
- markets.financialcontent.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.